文献速递前列腺癌

生理盐水辅助筋膜暴露微超声引导机器人前列腺癌根治术中神经保留:随机对照试验中期分析

Saline-assisted Fascial Exposure Microultrasound-guided Nerve Preservation During Robotic Prostatectomy: Interim Analysis of a Randomized Controlled Trial.
PubMed 文献 · Eur Urol Oncol · 2026-08-08

该随机对照试验比较微超声引导SAFE-RARP与标准RARP,主要终点为6个月勃起功能恢复(SHIM≥17)。中期分析纳入107例,SAFE组52% vs 对照组43%,绝对差8.5%(95%CI -10%至27%,单侧p=0.22),未跨越预设疗效边界;6周早期恢复率SAFE组更高(37% vs 21%,单侧p=0.032)。

要点

  • SAFE技术未达到6个月勃起功能恢复主要终点。
  • SAFE组6周早期勃起功能恢复率更高,但3个月差异缩小。
  • 两组控尿、肿瘤学结局和并发症率相似。

核心结论

  • 预设中期分析未达到6个月勃起功能恢复的主要终点。
  • 探索性分析提示SAFE组术后早期恢复更快,且未发现安全性或肿瘤学结局受损的证据。

研究设计与样本

  • 随机对照试验,患者1:1分配至微超声引导SAFE-RARP或标准RARP。
  • 共分析107例患者(SAFE组54例,对照组53例)。
  • 外科医生非盲,患者和结局评估者盲法。

主要发现

  • 6个月勃起功能恢复率SAFE组52% vs 对照组43%,绝对差8.5%(95%CI -10%至27%),单侧p=0.22,未跨越预设中期疗效边界。
  • 6周早期恢复率SAFE组37% vs 对照组21%(单侧p=0.032),3个月差异缩小。
  • 线性混合效应模型显示SAFE组SHIM改善更早,6个月时趋同。
  • 两组控尿、肿瘤学结局和并发症率相似。

关键数值与推荐

  • 主要终点为6个月勃起功能恢复(SHIM≥17)。
  • 预设中期分析采用单侧 pooled z 检验,组序贯 O'Brien-Fleming α消耗框架,中期疗效边界为单侧 p<0.002。

临床怎么用

  • SAFE技术可考虑用于希望早期恢复勃起功能的患者,但需告知6个月主要终点未达到。
  • 该中期分析结果属假设生成性,尚不能改变标准实践。

局限性

  • 预设中期分析性质。
  • 样本量相对较小。
  • 需要更长随访以确定功能差异的持久性和临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erectile dysfunction remains a major morbidity after radical prostatectomy. The SAFE technique uses real-time, micro-ultrasound-guided low-pressure hydrodissection to enable atraumatic nerve sparing. OBJECTIVE: We compared functional and oncologic outcomes of SAFE versus standard robotic-assisted radical prostatectomy (RARP). DESIGN, SETTING, AND PARTICIPANTS: In this randomized trial, patients were assigned 1:1 to micro-ultrasound-guided SAFE-RARP or standard RARP. Surgeons were unblinded; patients and outcome assessors were blinded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was erectile function recovery at 6 mo (SHIM ≥17), with secondary functional and oncologic outcomes. The primary endpoint was assessed at the prespecified interim analysis using a one-sided pooled z-test within a group-sequential O'Brien-Fleming α-spending framework (interim efficacy boundary, one-sided p < 0.002). RESULTS AND LIMITATIONS: A total of 107 patients were analyzed (SAFE, n = 54; control, n = 53). At 6 mo, erectile function recovery was higher with SAFE than with standard RARP (52% vs 43%; absolute difference 8.5%, 95% CI -10% to 27%; one-sided p = 0.22), without crossing the prespecified interim efficacy boundary. At 6 weeks, early recovery rates were higher with SAFE (37% vs 21%; one-sided p = 0.032), with a smaller difference at 3 mo. Linear mixed-effects modeling showed earlier improvement in SHIM with SAFE, with convergence by 6 mo. Continence, oncologic outcomes, and complication rates were similar between groups. Limitations include the prespecified interim nature of the analysis, the relatively small sample size, and the need for longer follow-up to determine the durability and clinical significance of functional differences. CONCLUSIONS: In this prespecified interim analysis, the primary endpoint of 6-mo recovery was not met. Exploratory analyses suggested earlier postoperative recovery with SAFE, without evidence of compromised safety or oncologic outcomes; these findings are hypothesis-generating.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Pedraza AM, Fatterpekar M, Joshi H, et al. Saline-assisted Fascial Exposure Microultrasound-guided Nerve Preservation During Robotic Prostatectomy: Interim Analysis of a Randomized Controlled Trial. Eur Urol Oncol. 2026. PMID: 42570880. doi:10.1016/j.euo.2026.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。